TRANSLATE

The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

How might IVIG therapy be used to treat infection after BCMA-targeted therapies in MM?

Featured:

Krina PatelKrina Patel

Nov 6, 2023

Learning objective: After reading this article, learners will be able to cite a new clinical development in multiple myeloma.


During the 20th International Myeloma Society Annual Meeting 2023, the Multiple Myeloma Hub was pleased to speak to Krina Patel, MD Anderson Cancer Center, Houston, US. We asked, How might intravenous immunoglobulin therapy (IVIG) therapy be used to treat infection after B-cell maturation antigen (BCMA)-targeted therapies in MM?

How might IVIG therapy be used to treat infection after BCMA-targeted therapies in MM?

In this interview Krina Patel opens by explaining how BCMA-targeted therapies, used to treat MM, can result in a higher rate of infection. Patel then goes on to explain the applications of IVIG to treat these infections, outlining which patients the treatment is most appropriate for, as well as the recommended dosing regimens. Patel concludes by discussing alternative methods for prophylaxis and treatment of infections in MM.